Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 20, 2020 - Issue 6
Submit an article Journal homepage
228
Views
16
CrossRef citations to date
0
Altmetric
Original Research

Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study

Irene RussoUnit of Dermatology, University of Padua, Padua, ItalyView further author information
,
Serena MiottoUnit of Dermatology, University of Padua, Padua, ItalyView further author information
,
Andrea SaponeriUnit of Dermatology, University of Padua, Padua, ItalyView further author information
&
Mauro AlaibacUnit of Dermatology, University of Padua, Padua, ItalyCorrespondence[email protected]
View further author information
Pages 673-678 | Received 07 Oct 2019, Accepted 05 Feb 2020, Published online: 13 Feb 2020

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Christian Ciolfi, Alvise Sernicola & Mauro Alaibac. (2022) Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability. Patient Preference and Adherence 16, pages 3035-3043.
Read now
Burçin Cansu Bozca, Aslı Bilgiç & Soner Uzun. (2022) Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus. Journal of Dermatological Treatment 33:4, pages 2102-2109.
Read now
Jessica McClatchy, Tami Yap, Kendrick Koo, Johannes S Kern & Laura Scardamaglia. (2021) De-escalation of anti-CD20 monoclonal antibody (Rituximab) protocols in Pemphigus Vulgaris – a systematic review. Expert Opinion on Biological Therapy 21:12, pages 1591-1601.
Read now
Soheil Tavakolpour, Zeinab Aryanian, Farnoosh Seirafianpour, Milad Dodangeh, Ifa Etesami, Maryam Daneshpazhooh, Kamran Balighi, Hamidreza Mahmoudi & Azadeh Goodarzi. (2021) A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns. Immunopharmacology and Immunotoxicology 43:5, pages 507-518.
Read now
Khalaf Kridin & A. Razzaque Ahmed. (2021) The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review. Expert Opinion on Biological Therapy 21:4, pages 443-454.
Read now

Articles from other publishers (11)

Tejas S. Athni & Sara Barmettler. (2023) Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. Annals of Allergy, Asthma & Immunology 130:6, pages 699-712.
Crossref
Linda Řandová & Ondřej Kodet. (2023) Effect of target therapy with BRAF and MEK inhibitors on the immune system in metastatic melanoma. Onkologie 17:2, pages 108-112.
Crossref
Khalaf Kridin, Noor Mruwat, Kyle T Amber & Ralf J Ludwig. (2023) Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study. British Journal of Dermatology.
Crossref
Namrata Singh, Sanjeev Handa, Rahul Mahajan, Naresh Sachdeva & Dipankar De. (2022) Comparison of the efficacy and cost-effectiveness of an immunologically targeted low-dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus. Clinical and Experimental Dermatology 47:8, pages 1508-1516.
Crossref
K. Simpson, Z.M. Low, T. Yap, J.S. Kern & L. Scardamaglia. (2021) Ultralow‐dose rituximab in pemphigus: a single‐centre experience. British Journal of Dermatology 186:3, pages 581-583.
Crossref
Yu‐An Wang, Julia Yu‐Yun Lee & Chao‐Chun Yang. (2021) Sustainable effect of ultra‐low dose rituximab for mild‐to‐moderate pemphigus vulgaris: A case report. The Journal of Dermatology 48:12.
Crossref
Hana Jedličková. (2021) Rituximab. Dermatologie pro praxi 15:2, pages 105-107.
Crossref
A. Pulido-Pérez, M. Bergón-Sendín, R. Suárez-Fernández, P. Muñoz-Martín & E. Bouza. (2021) Skin and sepsis: contribution of dermatology to a rapid diagnosis. Infection 49:4, pages 617-629.
Crossref
Roberto MAGLIE, Emiliano ANTIGA & Aimee S. PAYNE. (2021) B-cell targeted therapies in pemphigus. Italian Journal of Dermatology and Venereology 156:2.
Crossref
Jingfeng Xu & Qiuli Wu. (2021) Prediction on influenza-like virus pathogen and its effects on prognosis of patients with community acquired pneumonia under long and short term memory neural network model. Results in Physics 24, pages 104079.
Crossref
Gérôme Bohelay, Frédéric Caux & Philippe Musette. (2021) Clinical and biological activity of rituximab in the treatment of pemphigus. Immunotherapy 13:1, pages 35-53.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.